InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

Core Insights - InflaRx N.V. is set to report topline data from its Phase 2a clinical trial of oral C5aR inhibitor INF904 for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on November 10, 2025 [1] - The company will host a webcast/conference call on the same day to discuss the clinical data and feature insights from key opinion leaders [2] - InflaRx will also publish its third quarter 2025 financial and operating results via Form 6-K on the same day [3] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary anti-C5a and anti-C5aR technologies to develop specific inhibitors targeting the complement activation factor C5a and its receptor C5aR [4] - The company has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody, and is also working on INF904, an orally administered small molecule inhibitor [4] - Founded in 2007, InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA [5]